Proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease
26 June 2013
PHARMAC is seeking feedback on a proposal to widen access to imiglucerase from 1 September 2013.
In summary the proposal would result in
- patients with Gaucher disease Type 3 having access to funded imiglucerase;
- the maximum funded dose of imiglucerase being increased from 15 iu/kg per month to 30 iu/kg per month for children meeting certain criteria
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5pm Wednesday, 10 July 2013 to:
Therapeutic Group Manager
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Last updated: 3 March 2016